

Medicen Paris Region announces 20% business growth in 2016

Arrival of 80 new members and two-fold increase in regional and European funding were drivers for strong performance

Initiatives for SMEs central to 2016 strategy, with triple focus encompassing growth, financing and international expansion

Paris, May 18, 2017 - Medicen Paris Region, Europe's leading healthcare cluster, today announces its review of business for the previous year. The 20% growth in activity was reflected in the budget increase, from €1.9 million (\$2.06M) in 2015 to €2.3 million (\$2.49M) in 2016.

The rise in the cluster's activity is due to the surge in new members and the resulting membership fees (representing a 5.5% increase in value). Amongst these new members E-health companies lead the way – SMEs, large corporations and academic organizations – accounting for 42%, followed by medtech companies (26%), service providers (17%) and biotech companies (15%).

In parallel, since 2015 the Ile-de-France (Greater Paris) region and the European Regional Development Fund (ERDF) have more than doubled their financial support, from €245,000 (\$266K) to €573,000 (\$623K).

This funding increase has been invested in activities devised to support SMEs in their growth. It has more than doubled in the past year on a like-for-like payroll basis, rising by 141%. The areas of priority focus – growth, financing and international expansion – have been strengthened as follows:

- Growth: 2016 saw the market launch of some 15 products from the completion of 16 accredited projects
- International expansion: introduction of 14 schemes, including two development programs involving support for 60 SMEs and for 11 delegations to events with global reach
- During 2016, collaborative projects showed the same dynamism. Medicen Paris Region approved 17 collaborative projects¹ with a cumulative valued at €170 million (\$185M), including €58 million (\$63M) in public funding. During 2016, collaborative projects showed the same dynamism

"We are very pleased with these positive results for 2016, strong revenue growth has allowed us to invest in supporting our members," said Christian Lajoux, chairman of the Medicen Paris Region cluster. "The launch of an international committee at the end of last

¹ Four French National Research Agency (*Agence Nationale de la Recherche*, ANR) projects, two National Interest Contract (*Contrat d'Intérêt National*, CIN) projects, two ERDF projects, two Single Interministerial Fund (*Fonds Unique Interministériel*, FUI) projects, one R&D Competitiveness Development project (*Projet de recherche et de développement Structurant pour la Compétitivité*, PSPC) and six Teaching Hospital Health Research (*Recherche Hospitalo-Universitaire en santé*) projects

year helped us raise our profile and introduce coherent measures with a significant impact for our members.”

Medicen Paris Region plans to continue increasing its level of activity in 2017. Investment in measures for business development will grow by 35% compared with 2016. The cluster will also focus on specific initiatives to promote employment, training and human resources, with a three-fold budget increase to meet members’ demands.

About Medicen Paris Region

Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 300 companies, research centers, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe's leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, regenerative medicine and biomaterials, digital health and translational medicine. In close collaboration with local, regional and national healthcare innovation players, Medicen Paris Region aims to:

- Foster the emergence, development and funding of certified collaborative projects in the healthcare sector, in order to create economic value and jobs
- Increase the international development of innovative startups and SMEs
- Strengthen the attractiveness of the Paris region, which represents more than 50% of life sciences activity in France

Since the creation of the cluster in 2005, 57 innovative products have been launched in the imaging, medical devices and biological tools sectors. The cluster has certified 284 projects. They received funding from the French government (French Inter-Ministry Fund FUI, Structuring Projects fund), the public investment bank Bpifrance, the National Research Agency, the European Regional Development Fund, the Investments for the Future program and/or local authorities, and the Paris region. Total investment is close to €1.9 billion and €533 million of public aid.

www.medicen.org

Media and analyst contact Andrew Lloyd & Associates

Agnes Stephens / Lise Beltzung

agnes@ala.com - lise@ala.com

Tel: +44 1273 675 100

[@ALA_Group](#)